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ABSTRACT
Applying kinetics and footprinting analysis, we show
that telithromycin, a ketolide antibiotic, binds to
Escherichia coli ribosomes in a two-step process.
During the first, rapidly equilibrated step, telithromy-
cin binds to a low-affinity site (KT=500nM), in which
the lactone ring is positioned at the upper portion of
the peptide exit tunnel, while the alkyl–aryl side
chain of the drug inserts a groove formed by nucleo-
tides A789 and U790 of 23S rRNA. During the second
step, telithromycin shifts slowly to a high-affinity
site (KT*=8.33nM), in which the lactone ring
remains essentially at the same position, while the
side chain interacts with the base pair U2609:A752
and the extended loop of protein L22. Consistently,
mutations perturbing either the base pair
U2609:A752 or the L22-loop hinder shifting of telith-
romycin to the final position, without affecting the
initial step of binding. In contrast, mutation
Lys63Glu in protein L4 placed on the opposite side
of the tunnel, exerts only a minor effect on telithro-
mycin binding. Polyamines disfavor both sequential
steps of binding. Our data correlate well with recent
crystallographic data and rationalize the changes in
the accessibility of ribosomes to telithromycin in
response to ribosomal mutations and ionic changes.
INTRODUCTION
Macrolide antibiotics represent a large family of
polyketide compounds that act as inhibitors of bacterial
protein synthesis. They continue to enjoy a remarkable
interest within pharmaceutical industry, because many
have been already introduced in clinical applications,
while others are used as lead compounds in search for
new semisynthetic, anti-infectious agents with improved
pharmaceutical properties (1). Accumulated biochemical,
genetic and crystallographic evidences suggest that
macrolides exert their antimicrobial activity by binding
to approximately the same region of the large ribosomal
subunit, within a hydrophobic crevice of the peptide exit
tunnel, situated between the peptidyltransferase (PTase)
center and a constriction in the tunnel formed by proteins
L4 and L22 (2). By binding to this site, macrolides
hinder the progression of the nascent peptide chain
through the exit tunnel, which eventually falls off the
ribosome as oligopeptidyl-tRNA, in a process called
‘drop off’ (3). Although macrolides are accommodated
within the same binding pocket, their speciﬁc inter-
actions with the ribosome might vary in accordance
with the idiosyncratic chemical nature of each drug.
Tylosin, for instance, processing a mycaminose/
mycarose side chain (Figure 1), extends towards the
PTase center and, apart from occluding the exit tunnel,
inhibits peptide bond formation if the donor tRNA
bears a large amino acid (4).
Binding of an antibiotic to the ribosome is a prerequisite
for its action. Most of the earlier studies investigating the
kinetics of antibiotic interactions with the ribosome
operate on the assumption that the interaction between
ribosome (R) and antibiotic (I) can be expressed by a
fast-equilibrated reaction of the form: R+IÐRI (5–7).
In fact, this concession is not valid for macrolides. As
justiﬁed by kinetic studies (4,8–12), NMR and modeling
studies (13,14), and footprinting analysis at discrete
time-intervals following mixing the ribosome with the
drugs (4,12), access of macrolides to Escherichia coli ribo-
somes occurs through a two-step process; a ﬁrst rapidly
equilibrated step representing the recognition and selec-
tion of macrolides (I) by the ribosome (R), and a second
one corresponding to a slow isomerization of the encoun-
ter complex (RI) to a ﬁnal tight complex (R*I). In some
cases the binding was found to follow one-step mechanism
(3,9). Even in the latter cases, however, the inhibitor
retains its slow binding behavior.
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ance to macrolide antibiotics, extensive research on
the modiﬁcation of the prototype macrolide, erythro-
mycin, led to the development of ketolides (15,16).
Telithromycin is the ﬁrst ketolide introduced into clinical
practice. It differs from erythromycin by having a keto
group at the C-3 position of the lactone ring, instead of
the neutral sugar L-cladinose (Figure 1). In addition,
telithromycin has the 6-OH of the lactone methylated
and possesses an alkyl–aryl arm attached to carbamate
heterocycle that involves the C-11 and C-12 positions of
the lactone ring. Owing to its more elaborated chemistry,
telithromycin compared with erythromycin and other
newer macrolides exhibits superior clinical efﬁcacy in
upper and lower respiratory tract infections caused by
pathogens including strains resistant to macrolides (17).
Previous biochemical and genetic studies indicated that,
though telithromycin and erythromycin exploit the same
high-afﬁnity pocket in the ribosome, the speciﬁc inter-
actions of each drug vary in accordance with its
chemical nature. Speciﬁcally, apart from the interactions
between the hydrophobic face of the lactone ring and the
G2057–A2059 crevice of the exit tunnel, the binding of
telithromycin seems to beneﬁt from interactions of the
side chain with U2609 and the loop of helix 35 of 23S
rRNA (18–25). In this way, potential interactions of the
side chain with ribosomal residues placed deeper in the
exit tunnel may compensate for lost of the classical
2058–2059 contacts due to methylation or mutations and
gain weight in efﬁcient antibiotic binding. Earlier crystal-
lographic studies of telithromycin in complex with the
large ribosomal subunit of Deinococcus radiodurans
(D50S) and Haloarcula marismortui (H50S) failed, each
one, to whole verify the mutational and footprinting
proﬁle (26,27). In the D50S model, the side chain of telith-
romycin penetrates deeper into the tunnel and inserts into
a groove formed by nucleotides A764 (A751), A802
(A789) and C803 (U790) within domain II of 23S rRNA
(terms in parenthesis represent the equivalent residues in
E. coli). In the H50S model, the side chain is folded across
the lactone ring and stacks on nucleotide C2644 (U2609)
within domain V of 23S rRNA. Structural and functional
studies have demonstrated that cations play a signiﬁcant
role in macrolide–ribosome interactions (4,5,12,28,29).
Therefore, apart from species-speciﬁc structural ribosomal
differences, ionic environment differences between bacter-
ial and archeal ribosomes may conceivably cause an alter-
native drug conformation (30). Recent crystallographic
structures of ribosomes from two eubacteria, E. coli and
Thermus thermophilus, in complex with telithromycin seem
to address the disagreements between the H. marismortui
and D. radiodurans structural data (31,32). Nevertheless,
crystallographic structures provide only a snapshot of
telithromycin binding process and cannot describe the
entire course of unique conformations and spatial inter-
actions by which the drug gain access to the tight binding
site on the ribosome.
In the present study, kinetic analysis and footprinting
analysis at distinct binding-steps are applied to investi-
gate the entire course of telithromycin interaction
with wild-type or mutant E. coli functional ribosomal
complexes, under various ionic conditions. Together
Figure 1. Chemical structures of tylosin, erythromycin and telithromycin.
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previous uncertainties and offer new clues as to how telith-
romycin seeks out its ﬁnal position in the ribosome.
MATERIALS AND METHODS
Reagents, materials and strains
Spermine tetrahydrochloride, spermidine trihydrochloride,
dimethyl sulfate (DMS), DMS stop solution, puromycin
dihydrochloride, tylosin tartrate and tRNA
Phe from
E. coli were provided by Sigma-Aldrich. Kethoxal
was from MP Biomedicals, while 1-cyclohexyl-3-
(2-morpholinoethyl) carbodiimide metho-p-toluene
(CMCT)wasfromFlukaBiochemicals.Radioactivemater-
ials were from Amersham Biosciences. AMV reverse tran-
scriptase, dNTPs and ddNTPs were from Roche
Diagnostics. Telithromycin was kindly provided by
Sanoﬁ-Aventis Inc. Cellulose nitrate ﬁlters (type HA;
0.45mm pore size) were from Millipore Corp.
Erythromycin-resistant strains N281 and N282 of E. coli,
mutated in ribosomal protein L22 (deletion of methionine,
lysine and arginine at positions 82–84, here referred to as
82–84) and in L4 (a single amino acid substitution at
position63,herereferredtoasLys63Glu)(33),respectively,
were kindly provided by Dr S.T. Gregory (Brown
University). Escherichia coli TA531 cells lacking chromo-
somal rrn alleles, but containing pKK35 plasmids possess-
ing wild-type or mutated 23S rRNA (U2609C or U754A)
were kindly provided by Dr A.S. Mankin (University of
Illinois).
Biochemical preparations
70S ribosomes, Ac[
3H]Phe-tRNA charged to 80% and a
post-translocation complex of poly(U)-programmed ribo-
somes, complex C, carrying tRNA
Phe at the E-site and
Ac[
3H]Phe-tRNA at the P-site were prepared as described
previously (34). The percentage of complex C, reactive
towards puromycin, was>90%.
Kinetics of telithromycin interaction with complex
C containing wild-type or mutated ribosomes
As previously proved (4), tylosin inhibits the puromycin
reaction, a model reaction for peptide bond formation,
since this macrolide possesses a long dissacharide chain
extending towards the PTase center and perturbing the
positioning of the 30-end of P-site bound AcPhe-tRNA
(Figure 1). Telithromycin does not inhibit the puromycin
reaction, however, it competes with tylosin for
overlapping binding sites on the ribosome. Taking advan-
tage of this competition, we added complex C into buffer
A [100 mM Tris/HCl, pH 7.2, 4.5mM Mg(CH3COO)2,
150mM NH4Cl, 6mM b-mercaptoethanol] containing
4mL tylosin and telithromycin at speciﬁed concentra-
tions. The mixture was incubated at 25 C for the desired
time intervals and the process of the reaction was
monitored by titrating the remaining activity of
complex C with puromycin (2mM, 25 C). In parallel
experiments, complex C was pre-incubated with telithro-
mycin for 15min and then added in the solution of tylosin.
Since telithromycin, like erythromycin (4), binds to
complex C via two sequential reactions, the ﬁrst one pro-
ceeding much faster than the subsequent isomeri-
zation step, the competition between telithromycin
(T) and tylosin (I) for complex C can be described by
kinetic Scheme 1. Therefore, data processing and calcula-
tion of the values of KT, kon,T and koff,T constants were
done in an analogous way to those previously used for
kinetic analysis of erythromycin binding (see supplemen-
tary material in ref. 4). The dissociation constant
KT*, representing the overall afﬁnity of complex C
for telithromycin, was calculated through the
relationship (35),
K 
T ¼ KT
koff,T
kon,T+koff,T

ð1Þ
To estimate the koff,T value by an alternative way and to
calculate how many molecules of telithromycin bind per
E. coli ribosome, complex C*T (10pmol) absorbed on a
cellulose nitrate ﬁlter was immersed in 5ml of buffer
A containing 4mL tylosin for speciﬁed time intervals.
After removing the excess of tylosin by fast washing
with buffer A, the percentage (x) of complex C*T remain-
ing active was titrated with 2mM puromycin. At dilution,
rebinding of telithromycin to ribosomes is negligible, and
the rate of dissociation corresponds to the koff of the
telithromycin–ribosome complex. Therefore, the koff,T
value was estimated from the slope of the obtained
semi-logarithmic time plot.
Probing of CT and C*T complexes
Complex C (10pmol) was incubated in the absence or pres-
ence of 2.5mL telithromycin (50 KT) in 100ml buffer B
[50 mM HEPES/KOH, pH 7.2, 4.5mM Mg(CH3COO)2,
150mM NH4Cl, and 5mM dithiothreitol] at 25 C, either
for 5s (CT probing) or for 8 t1/2min (C
*T probing). The
term t1/2 represents the half life for the attainment of equi-
librium in complex C interaction with telithromycin and is
given by the Equation 2,
t1=2 ¼
0:693
k00 ð2Þ
where k00 is the apparent equilibration rate constant, given
by Equation 3.
k00 ¼ koff,T+kon,T
½T 
KT+½T 
ð3Þ
Probing of CT and C*T complexes with DMS, kethoxal
and CMCT, and monitoring of the modiﬁcations in
23S rRNA were performed by primer extension analysis,
according to Stern et al. (36). Extension products were run
on 6% polyacrylamide/7M Urea gels. Quantiﬁcation and
normalization of band intensities were done as described
previously (4). The values indicated in Table 3 denote the
ratio between the intensity of a band of interest and
the intensity of the corresponding band obtained in the
absence of telithromycin.
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wild-type or mutant ribosomes
Cells (400ml of a 0.700 OD560 preculture) were added in
3.6ml of LB medium and grown at 37 C in the presence or
absence of telithromycin until the optical density of the
control culture (grown in the absence of telithromycin)
reached the value 0.700 at 560nm. From the curves
obtained, the IC50 value for each strain was estimated as
the concentration of telithromycin that is required to bring
the corresponding curve optical density down to point half
way between the value 0.700 and bottom plateau.
Statistics
All data shown in Tables or kinetic diagrams denote
mean values obtained from three independently per-
formed experiments. Data variability was determined by
ANOVA, while signiﬁcant differences between mean
values were measured by the F-Scheffe ´ test (SPSS
program 17.0 for Windows).
RESULTS
Telithromycin behaves as a slow-binding ligand
of ribosomes, following a two-step mechanism
Previous studies have showed that tylosin inhibits the
AcPhe-puromycin synthesis at 4.5mM Mg
2+and
150mM NH4
+, following a two-step mechanism (4,12).
In contrast, as shown in Figure 2A, telithromycin fails
to inhibit this model reaction. This renders the kinetic
analysis of telithromycin interaction with complex
C impossible, if the PTase activity is monitored.
Nevertheless, tylosin and telithromycin exhibit an
overlapping footprinting pattern predicting that telithro-
mycin competes with tylosin for binding to complex C.
Indeed, as shown in Figure 2B, complex C addition in a
solution containing tylosin at 4mL and telithromycin
at increasing concentrations results in non-linear inactiva-
tion curves, whose initial slopes vary as a function of
telithromycin concentration. At high concentrations of
telithromycin (>10mL), the inactivation of complex C
by tylosin is entirely reversed. Interestingly, when
complex C is preincubated for 15min with telithromycin
Figure 2. Kinetics of telithromycin. (A) AcPhe-puromycin synthesis in
the absence or presence of antibiotics; complex C prepared from E. coli
ribosomes was reacted in buffer A at 25 C with 200mL puromycin
alone (ﬁlled circle), or with a mixture containing both 200mL puro-
mycin and 2mL telithromycin (ﬁlled square), or 200mL puromycin
and 2mM tylosin (ﬁlled triangle). (B) effect of telithromycin on the
inactivation of complex C by tylosin; complex C was incubated in
buffer A with 4mL tylosin alone (ﬁlled square), or with a mixture
containing 4mL tylosin and telithromycin at 0.5 (open circle),
1 (ﬁlled circle), 2 (ﬁlled triangle), 4 (ﬁlled inverted triangle), and
10mL (ﬁlled rhombus). The percentage of the complex C input remain-
ing active, x, was determined with 2mM puromycin (25 C, 2min).
(C) pre-incubation effect; complex C was incubated in buffer A with
4mL tylosin alone (ﬁlled square), or with a mixture containing 4mL
tylosin and telithromycin at 1mL (ﬁlled circle), or ﬁrst pre-incubated
with 1mL telithromycin for 15min, and then reacted with 4mL tylosin
for the time intervals indicated (open circle). The x value was
determined as stated in (B).
Scheme 1. Competition between telithromycin (T) and tylosin (I) for
binding to ribosomal complex C.
Nucleic Acids Research, 2012,Vol.40, No. 11 5081before adding tylosin, the protection of complex C
against tylosin becomes stronger (preincubation effect;
Figure 2C). This inactivation pattern is reminiscent of
that observed in a previous study regarding erythromycin
binding (4), and strongly suggests adopting a similar
kinetic model, which here is represented by Scheme 1.
The values of kon,T, koff,T and KT calculated by kinetic
analysis are shown in Table 1 (for kinetic Equations and
data processing, see Supplementary Data). A value of
8.33 10
 3min
 1 estimated for koff,T from the slope of
the diagram shown in Figure 3, is quite similar to that
presented in Table 1. A second information drawn from
Figure 3 is that complex C regeneration from complex
C*T gives a simple ﬁrst-order time plot, suggesting one
molecule of telithromycin bound per E. coli ribosome.
By repeating experiments in the presence of 100mL
spermine or in an optimized polyamine buffer (50mL
spermine and 2mM spermidine; ref. 37), we observed
that the KT value undergoes at least a 3-fold increase,
whereas kon,T value and the isomerization constant
kon,T/k off,T are decreased by 83 and 64%, respectively
(Table 1).
Regarding the impact of mutations on telithromycin
binding, U2609C and L22: 82–84 show the stronger
effects. Both mutations cause a 20-fold enhancement on
the overall afﬁnity constant J*T, by decreasing the kon,T
value and increasing the koff,T value. Instead, both muta-
tions hardly affect the KT value. Mutation U754A exhibits
a less pronounced effect, doubling the value of koff,T
constant, while mutation Lys63Glu in L4 does not essen-
tially affect telithromycin binding (Table 1). Evidence in
corroboration was sought in experiments assessing the
in vivo sensitivity of E. coli strains against telithromycin.
As shown in Table 2, the IC50 values measured in
wild-type cells or mutants U754A and L4: Lys63Glu are
much smaller than in U2609C or L22: 82–84 mutants.
Footprinting analysis of CT and C*T complexes
The ﬁrst step of telithromycin binding to complex C is
presented by a bimolecular reaction. Therefore, to foot-
print the CT complex, telithromycin at concentration
50 KT and complex C at 100nM were incubated
at 25 C for 5 s. Since the equilibrium C+TÐCT is
established instantaneously while the subsequent isomeri-
zation step proceeds slowly, the species mainly produced
during this time interval is complex CT (>97%). By longer
exposure of complex C to telithromycin (8 t1/2), the high
value, 58.93, for the isomerization constant of the second
step favors the formation of C*T complex (>98%). Next
to their formation, complexes CT and C*T were probed
with DMS, CMCT or kethoxal. Noteworthy, the chemical
probes used react with accessible bases within milliseconds
(38). Representative autoradiograms obtained by primer
extension analysis in helix 35 of domain II and the central
loop of domain V of 23S rRNA are shown in Figure 4,
while relative reactivities of the modiﬁed nucleotides are
summarized in Table 3. To assess the footprinting changes
relative to the rest of neighboring 23S rRNA areas,
larger regions of the scanned sequences are given in
Supplementary Figures S1 and S2. Telithromycin in the
CT binding state and in the absence of polyamines
strongly protects A2058, A2059 and to a lesser degree
G2505, C2611, A752, A789 and U790. In contrast, it
causes an enhancement in the susceptibility of A2062 to
DMS. In the C*T binding state, the protection effects at
A789 and U790 soften, the protection at A752 enhances,
while a new protection appears on U2609.
Spermine, either alone or in a mixture with spermidine,
reduces the protection of all nucleotides involved in
telithromycin binding, in particular of U2609 and A752
in complex C*T, and of A2058 in both complexes.
Interestingly, in the presence of polyamines, the reactivity
of C2611 is lost in either complex. This phenomenon, also
observed previously (4,12), may be related to a stabiliza-
tion effect that polyamines exert on the C2611/G2057 base
pair at low concentrations of Mg
2+.
DISCUSSION
Crystallographic studies of ribosomal subunits complexed
with telithromycin presents an extended panel of detailed
view of the ribosome–drug interactions at atomic
resolution. Nevertheless, these studies often use fairly
artiﬁcial complexes that do not reproduce the ionic
cell-environment, and worse still provide only a
snapshot of telithromycin binding process. In the present
Table 1. Equilibrium and kinetic constants derived from analysis of the telithromycin binding to complex C
a
Constant (unit) Ionic conditions
4.5mM Mg
2+, 150mM NH4
+ 4.5mM Mg
2+,
150mM NH4
+
100mL spermine
4.5mM Mg
2+
150mM NH4
+
50mL spermine
2mM spermidine
Wild-type U2609C U754A L22: 82–84 L4: Lys63Glu Wild-type Wild-type
KT (nM) 500±44 536±43 604±45 530±42 470±48 2500±185 1714±13
kon,T (min
_1) 0.480±0.040 0.103±0.008 0.430±0.040 0.046±0.005 0.290±0.050 0.078±0.006 0.082±0.006
koff,T (min
_1) 0.0082±0,0006 0.0395±0.0031 0.0166±0.0014 0.0300±0.003 0.0076±0.0008 0.0029±0.0002 0.0038±0.0001
kon,T/k off,T 58.93±6.52 2.61±0.29 25.90±3.25 1.53±0.22 38.16±7.71 26.90±2.77 21.58±1.90
K*T (nM) 8.33±1.16 148.00±18.92 22.60±3.22 210.00±30.93 12.00±2.67 91.40±11.24 75.70±8.80
aData represent the mean±SE values obtained from three independently performed experiments.
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discrete time-intervals following mixing the ribosome with
the drug give us the opportunity to investigate the entire
course of telithromycin binding to E. coli functional ribo-
somes, under near physiological ionic conditions.
Our results indicate that telithromycin interacts with a
model post-translocation ribosomal complex C, at 4.5mM
Mg
2+ and 150mM NH4
+, via a two-step mechanism.
Supportive evidence for the consistency of this model
with our kinetic results is provided by the following
ﬁndings: ﬁrst, the initial slopes of the inactivation curves
in Figure 2B vary as a function of the telithromycin con-
centration, second, the k versus [telithromycin] plot is rep-
resented by a rectangular hyperbolic curve (data not
shown) and, third, the potency of telithromycin to
reverse the inactivation of complex C by tylosin increases
if complex C is pre-incubated with telithromycin before
adding tylosin (pre-incubation effect; Figure 2C).
In addition, the apparent association rate constant of
telithromycin binding, (kon,T +k off,T)/KT, equals
1.6 10
4M
-1s
-1 a value two orders of magnitude below
the upper limit set for the characterization of a drug as
a slow binding, slowly reversible ligand (35). Moreover,
the value of the isomerization constant, kon,T /k off,T,i s
much higher than 1. Based on these results, we suggest
that an initial and rapidly equilibrated step is followed
by a slow isomerization step which facilitates accommo-
dation of the drug at its ﬁnal position. Binding of telith-
romycin at the initial and ﬁnal positions is mutually
exclusive, which means that only one molecule of telithro-
mycin binds per ribosome at a time. A similar conclusion
is also drawn by regeneration of complex C from complex
C*T, which follows a linear ﬁrst-order time-plot
(Figure 3). A drug:ribosome stoichiometry equal to one
has also been determined previously, by titrating the ribo-
somal binding site for telithromycin via footprinting
analysis (18).
At 4.5mM Mg
2+ and 150mM NH4
+, telithromycin
shows a slightly higher overall afﬁnity for the complex C
target than does erythromycin (4), but displays a signiﬁ-
cantly lower afﬁnity than those of azithromycin (12)
and 16-membered lactone ring macrolides (4,29).
A similar order of potency has also been assigned to
these antibiotics on the basis of KD values calculated
by ﬂuorescence polarization (39). Binding of telithromycin
to complex C is affected by polyamines at both
steps; KT value becomes over 3-fold higher, whereas the
isomerization constant undergoes a 50% reduction.
Although the value of KT* becomes 10-fold higher, telith-
romycin retains its relative potency compared to the other
antibiotics, because parallel alterations are caused by the
polyamine buffer in the kinetic constants of the latter
drugs (4,12,29).
The slow dissociation of complex C*T (koff.T=0.0082/
min) acquires pharmaceutical signiﬁcance. Binding of
telithromycin at the exit tunnel constriction jams the
tunnel, causing arrest to protein synthesis, a fact eventu-
ally leading to drop off of peptidyl-tRNA from the
ribosome (3). Since koff.T is 10 times lower than the rate
constant for drop off calculated by Lovmar et al. (3), it is
predicted that telithromycin at saturating concentrations
might completely shut down the elongation of nascent
peptides. Instead, erythromycin has a koff value almost
equal to the rate constant for drop off (4), a fact render-
ing dissociation of erythromycin equally probable.
Consequently, sensitivity of the ribosome against erythro-
mycin is less pronounced. There is also an apparent rela-
tionship between koff value and post-antibiotic effect
(PAE) (40), in that telithromycin has slower dissociation
rate and longer PAE compared with erythromycin,
leading in other words to longer persistent antibacterial
effects after drug removal from the growth medium.
The structural characterization of complexes CT and
C*T was obtained by footprinting analysis. As shown in
Table 3, telithromycin binding at the initial site (complex
CT) protects G2505, nucleotides clustered around a
hydrophobic crevice (nts: G2057- A2059) placed at the
entrance to the exit tunnel, and nucleotides in domain
II of 23S rRNA positioned further down the peptide
exit tunnel (nts: A752, A789, U790). Meanwhile, the
reactivity of A2062 against DMS becomes stronger.
The footprinting pattern of complex CT does not
Figure 3. Dissociation of telithromycin from complex C*T; complex
C*T formed by incubating complex C in buffer A with 2.5mL telith-
romycin at 25 C for 15min was adsorbed by ﬁltration on a cellulose
nitrate ﬁlter, exposed to 5ml of 4mL tylosin in buffer A for the time
intervals indicated, and the percentage of complex C*T remaining
active, x, was titrated with puromycin.
Table 2. Half maximal inhibitory concentrations (IC50) for telithro-
mycin, indicating how much of the drug is needed to inhibit the
growth of wild-type E. coli cells or mutants by half
a
Mutation IC50 (mg/ml)
None 4.0±0.8
L4: Lys63Glu 12.0±2.1*
U754A 14.8±2.5*
U2609C 41.6±4.3*
, **
L22: 82–84 50.0±6.5*
, **
aData represent the mean±SE values obtained from three independ-
ently performed experiments.
*Signiﬁcantly different in relation to wild-type cells (P<0.05);
**Signiﬁcantly different in relation to L4: Lys63Glu or U754A
mutants (P<0.05).
Nucleic Acids Research, 2012,Vol.40, No. 11 5083signiﬁcantly differ to that published for telithromycin–
ribosome interaction by other groups (18,20), except for
the absence of protection at U2609, the appearance of new
protections at A789 and U790, and the relatively weaker
protection at A752. It correlates well with crystallographic
data obtained with D. radiodurans 50S ribosomal subunit
in complex with telithromycin (26). In this crystallo-
graphic study, the alkyl–aryl arm of telithromycin does
not orient toward U2609, but inserts into a groove
formed by nucleotides A751, A789 and U790 within
Figure 4. Protections in nucleotides of 23S rRNA from chemical probes, caused by binding of telithromycin to complex C prepared from E. coli
ribosomes. (A) protections in domain II of 23S rRNA; complex C was incubated in the absence or presence of telithromycin in buffer B (lanes 1–4)
or in the same solution also containing 100mL spermine (lanes 5–8). The resulting complexes were then probed with DMS or CMCT. U, A, G and
C, dideoxy sequencing lanes; lane 2 and 6, complex C probed in the absence of telithromycin; lanes 3 and 7, complex C pre-incubated with
telithromycin for 5s and then probed; lanes 4 and 8, complex C pre-incubated with telithromycin for 15min and then probed. (B) protection in
the central loop of domain V of 23 S rRNA; incubation of complex C with telithromycin was carried out as in panel A. Samples were then modiﬁed
with DMS, kethoxal, or CMCT, and analyzed as in panel A. Numbering of nucleotides for the sequencing lanes is indicated at the left of each panel,
while nucleotides with reactivity to probes along with reference bands are shown by arrows. Teli, telithromycin.
Table 3. Footprinting of the telithromycin binding sites in the initial (CT) and the ﬁnal (C*T) binding site
a
23S rRNA residue Ionic conditions
4.5mM Mg
2+ 150mM NH4
+ 4.5mM Mg
2+150mM NH4
+100mL spermine
C CT C*T C CT C*T
A752 1 0.65±0.05* 0.30±0.02*
, ** 1 0.75±0.05* 0.87±0.07*
A789 1 0.78±0.07* 0.89±0.08 1 0.82±0.08* 0.93±0.08
U790 1 0.60±0.07* 0.85±0.08*
, ** 1 0.70±0.07* 0.93±0.08**
A2058 1 0.20±0.02* 0.25±0.03* 1 0.30±0.01* 0.38±0.02*
, **
A2059 1 0.38±0.03* 0.42±0.03* 1 0.45±0.05* 0.57±0.03*
, **
A2062 1 1.33±0.18* 1.28±0.15* 1 1.20±0.14 1.15±0.14
G2505 1 0.65±0.09* 0.78±0.11* 1 0.72±0.07* 0.85±0.06*
U2609 1 0.95±0.07 0.72±0.04*
, ** 1 0.97±0.07 0.90±0.08
C2611 1 0.60±0.09* 0.60±0.08* 1 0.98±0.05 0.97±0.05
aRelative reactivity of nucleotides denotes the ratio between the intensity of a band of interest and the intensity of the corres-
ponding band in the control lane (complex C). Only residues, whose reactivity changes upon exposure to telithromycin, are
shown.
*Signiﬁcantly different in relation to C for the same ionic conditions (P<0.05); **Signiﬁcantly different in relation to CT for
the same ionic conditions (P<0.05)
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of differences in the sequence and structures between D.
radiodurans and E. coli in this region of 23S rRNA, and a
putative rotation of U790 from position (a) to position (b)
upon binding of telithromycin to the initial site should be
assumed to explain a stacking interaction of the telithro-
mycin side chain against the base of U790 (Figure 5). The
lack of protection effects at U2609 does not support the
proposal that the formation of a base pair between U2609
and A752 is induced upon initial binding of telithromycin
to the ribosome (30). Such a pairing, detected by recent
crystallographic studies in E. coli ribosomes complexed
with telithromycin (31), might be a delayed event induced
by conformational changes occurring during the next
isomerization step (see below). Corroborative evidence is
coming from kinetic studies involving ribosomes bearing
mutation U2609C; no impact of this mutation on KT
value is evident (Table 1). In the presence of spermine, a
general softening of protections is notable. This may be
due toone or moreof thefollowing reasons:(i) inactivation
of the chemical probes by freely circulating spermine (41);
(ii) competition between spermine and chemical probes for
binding to certain residues of 23S rRNA; and (iii) conform-
ationchangesinducedbyspermineandleadingtoinhibition
oftelithromycinbindingtoribosomes.Althoughwecannot
completely disregard the two ﬁrst possibilities, kinetic
results are tempting us to adopt the third hypothesis. As
shown in Table 1, the presence of spermine causes a 5-fold
decreaseintheafﬁnityoftelithromycinfortheinitialsite.As
indicated before, spermine is capable of binding to riboso-
mal regions implicated in telithromycin accommodation,
and induces conformational changes on the ribosome
(42).Similarobservationswereobtainedwhenanoptimized
mixture of spermine and spermidine was used instead of
spermine alone.
The footprinting pattern of complex C*T resembles
better those published by others and generally correlates
well with recent crystallographic data obtained with
ribosomes from T. thermophilus and E. coli, complexed
with telithromycin (31,32). This may be due to the fact
that both footprinting and crystallographic analyses have
beenperformed byincubatingribosomes withhighconcen-
trations of telithromycin for prolonged time.
Accommodation of telithromycin at its ﬁnal position
weakens the contacts with nucleotides A789, U790 and
G2505, but favors drug interactions with A752 and U2609
(Table 3). In excellent agreement, U754A destabilizes
complex C*T (Table 1); U754 base pairs with A743, and
therefore, U754A may disrupt helix 35 in domain II of
23S rRNA, thus indirectly affecting the conformation of
A752 which contacts telithromycin (31,32). In addition,
U2609C mutation prevents C*T formation by hindering
the shift of telithromycin to the high afﬁnity site and
destabilizing the ﬁnal complex C*T. Similarly, deletion of
three amino acids in the ﬁnger-like b-hairpin of ribosomal
protein L22 disfavors the formation of complex C*T,
without affecting the ﬁrst step of telithromycin binding
(Table 1). In contrast, mutation Lys63Glu in a ﬁnger-like
extension of ribosomal protein L4 does not signiﬁcantly
alter the kinetics at both steps of telithromycin binding.
However, the same mutation, causes a 380-fold reduction
in the dissociation constant (KD) for erythromycin–
ribosome complex, rendering this mutant resistant to
erythromycin (43). The tips of the ﬁngers from L22 and
L4 along with rRNA residues form what appears to be a
constrictionattheuppersegmentoftheexittunnel,nearthe
PTase center (44). Namely, the ﬁnger-like extension of L4
projects towards the tunnel wall, where the hydrophobic
crevice G2057-A2058-A2059 is located. The tip of L22
ﬁnger-like b-hairpin is orientated towards the opposite
side of the tunnel wall and interacts with helix 35 in
domain II of 23S rRNA (Figure 5). We suppose that
deletion 82–84 in L22 results in a change of the overall
orientation of the tip of hairpin, which in turn perturbs the
interactionofthehairpin-tipwithhelix35,leadingﬁnallyto
disruption of the A752–U2609 base pair. Cryo-electron
microscopy (cryo-EM) data have suggested a broadening
ofthepeptideexittunnelbytheL22:82–84mutation(45).
Therefore, one could hypothesize that drug-dependent
blockage of the nascent peptide chain progression through
the exit tunnel may be by-passed by tunnel widening due to
the L22: 82–84 mutation. Instead, our results show a
25-fold increase in the overall dissociation constant K*T,a
10-fold reduction in association rate constant kon,T, and
about 4-fold enhancement in dissociation rate constant
koff,T by the L22: 82–84 mutation. These kinetic changes
justify that telithromycin resistance is likely conferred by
perturbation of the drug kinetic properties, making the
nascent chain by-pass model less convincing. In corrobor-
ation of this argument, crystallographic data have
suggested that the apparent broadening of the exit tunnel
seen by cryo-EM is due to the ﬂexibility of the mutant L22
loop rather than to a widening of the tunnel (27).
Polyamines exert again an inhibitory effect on the forma-
tion and stability of complex C*T (Table 1).
Figure 5. Stepwise binding of telithromycin to E. coli ribosomes. 50S
subunit cross-section showing the upper segment of the peptide exit
tunnel. (A) and (B), models of telithromycin binding at the initial
and ﬁnal site, respectively. A putative rotation of U790 from position
(a) to position (b) upon binding of telithromycin to the initial site is
indicated by a double arrow. The subunit structure was drawn from the
coordinates of Schuwirth et al. (46), while the modeling of telithromy-
cin binding was derived from footprinting results of the present study.
Nucleic Acids Research, 2012,Vol.40, No. 11 5085Our results reconcile a large body of experimental data,
and suggest a two-step drug binding mechanism, whereby
telithromycin is recognized by an initial subsite of the
E.coli ribosome to allow the drug to sequentially
progress toward a ﬁnal favorable orientation (Figure 5).
While the initial orientation is reminiscent of that crystal-
lographically seen in D. radiodurans, accommodation at
the ﬁnal position orientates the extended arm of telithro-
mycin in such a way, so that the aryl-end of the extension
stacks on the A752–U2609 base pair formed during the
shift of the drug from the initial to the ﬁnal position.
In contrast, the macrolactone portion remains at essen-
tially the same position, except for a slight movement un-
covered by small alterations in protection of nucleotides
A2058, A2059, A2062 and G2505. Although not accurate
enough for proper quantiﬁcation, these small changes
suggest that telithromycin may tolerate some perturb-
ations to the primary binding site by picking up new
binding from the stacking interactions of the alkyl–aryl
side chain. Finally, combined with crystallographic data,
our results support the notion that the precise placement
of a drug molecule can vary not only in ribosomes of dif-
ferent species, but also in the same species under different
ionic conditions or at different phases of its
accommodation with the ribosome.
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